Close Menu

NEW YORK – NeoImmuneTech on Wednesday announced that it would work with Roche on a Phase II trial to evaluate its lead drug candidate, NT-17, in combination with atezolizumab (Roche's Tecentriq) as a treatment for patients with locally advanced or metastatic non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.